Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 1,133 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 1,133 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $20.06, for a total transaction of $22,727.98. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Anish Patel also recently made the following trade(s):

• On Tuesday, May 14th, Anish Patel sold 1,107 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $27,675.00.
• On Thursday, May 9th, Anish Patel sold 260 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.06, for a total transaction of $6,515.60.
• On Monday, May 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.72, for a total value of $110,760.00.
• On Thursday, April 11th, Anish Patel sold 17,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.03, for a total transaction of $438,025.00.
• On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total value of $90,675.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN traded up $1.64 during midday trading on Monday, reaching $22.58. The stock had a trading volume of 199,511 shares, compared to its average volume of 254,581. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.70 and a beta of 1.11. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $26.00. The stock has a 50-day moving average of $20.87 and a 200-day moving average of $16.69.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. As a group, analysts forecast that Enliven Therapeutics, Inc. will post -2.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Mizuho started coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. AJOVista LLC purchased a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $28,000. China Universal Asset Management Co. Ltd. bought a new position in Enliven Therapeutics during the fourth quarter valued at approximately $66,000. Exchange Traded Concepts LLC grew its holdings in Enliven Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after buying an additional 2,208 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics in the 1st quarter worth approximately $167,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 9.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after acquiring an additional 1,029 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.